The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 01, 2025
Filed:
Aug. 03, 2020
Increasing cancer cells' sensitivity to tumor treating fields (ttfields) by inhibiting il11 activity
Applicant:
Novocure Gmbh, Root, CH;
Inventor:
Tali Voloshin-Sela, Kibbutz Gvat, IL;
Assignee:
Novocure GmbH, Baar, CH;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61N 1/00 (2006.01); A61B 18/12 (2006.01); A61K 9/00 (2006.01); A61K 31/4412 (2006.01); A61N 1/32 (2006.01); A61N 1/36 (2006.01); A61P 35/00 (2006.01); C07K 16/24 (2006.01); C07K 16/28 (2006.01); A61B 18/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4412 (2013.01); A61B 18/12 (2013.01); A61K 9/0019 (2013.01); A61N 1/32 (2013.01); A61N 1/36002 (2017.08); A61P 35/00 (2018.01); C07K 16/244 (2013.01); C07K 16/2866 (2013.01); A61B 2018/00613 (2013.01); A61K 45/06 (2013.01);
Abstract
A reduction in viability of cancer cells (e.g., glioblastoma) and a reduction in tumor volume can be achieved by applying a 100-500 kHz (e.g., 200 kHz) alternating electric field to the cancer cells and inhibiting IL11 (interleukin-11) activity and optionally administering and anti-fibrotic agent. The inhibiting of IL11 activity may be accomplished, for example, by decreasing IL11 expression, inhibiting IL11 signaling, downregulating IL11, neutralizing IL11, blocking an IL11 receptor, administering an IL11 antagonist, administering an IL11 neutralizing antibody, or administering an IL11 receptor α (IL11Ra) neutralizing antibody.